Sentences with phrase «multicenter phase»
METHODS: Three hundred seventy - two patients with mild to moderate AD were randomized to receive IM injections of AN1792 or placebo (4:1) at baseline and at months 1, 3, 6, 9, and 12 in a multicenter Phase II safety, tolerability, and pilot efficacy study.
http://www.sens.org/
An Open - Label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-Tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY 1251152 in Patients with Advanced Hematological Malignancies
An Open - Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B - 6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Results of this multicenter phase III study called HAVEN 1, will be presented at the International Society of Thrombosis and Hemostasis and published in the New England Journal of Medicine on July 10.
Results of a multicenter phase 1 clinical trial presented today at the 2015 San Antonio Breast Cancer Symposium show that the anti-androgen agent enzalutamide is active and well - tolerated alone and with fulvestrant in patients with advanced breast cancer.
Not exact matches
Promising results of an earlier, initial, multicenter clinical trial of nivolumab, first reported in 2013 and directed by Brahmer, led to the current phase III trial of 260 patients treated at hospitals across the world.
A total of 2,129 patients with mild dementia due to Alzheimer's disease participated in the double - blind, placebo - controlled, phase 3 multicenter trial.
The phase 1b multicenter trial included 21 patients on three continents, all of whom had metastatic melanoma.
«Autologous stem cell transplant should be standard care for HIV - associated lymphoma: Multicenter, Phase II trial suggests autologous transplant should be standard of care for HIV patients with relapsed / treatment - resistant lymphoma.»
A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer
A Phase 1, First - in - Man, Multicenter, Open - Label, Two Part Dose - Escalation and Cohort Expansion Study of Single - Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma
A Phase 3, Multicenter, Randomized, Double - Blind, Placebo - Controlled Study of AG - 120 in Previously - Treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation
A Phase 3 Open - label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
A Phase 1/2, Multicenter, Open - label Study of FT - 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
A Phase 1, Multicenter, Open - Label, Safety Study of AG - 120 or AG - 221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and / or IDH2 Mutation
A Phase III, Multicenter, Randomized, Placebo - Controlled, Double - Blind Study Of Atezolizumab (Anti − PD - L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy
A Phase III, Multicenter, Randomized, Placebo - Controlled Study of Atezolizumab (ANTI − PD - L1 Antibody) as Monotherapy and in Combination with Platinum - Based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma
A Multicenter, Randomized, Open - label, 3 - Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan / Cetuximab or Infusional 5 - Fluorouracil (5 - FU) / Folinic Acid (FA) / Irinotecan (FOLFIRI) / Cetuximab with a Safety Lead - in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E - mutant Metastatic Colorectal Cancer
A Phase 3, Multicenter, Randomized, Open - Label Study of Guadecitabine (SGI - 110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
An Open Label, Multicenter, Single Arm Phase II Pilot Study to Evaluate the Efficacy and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK - 228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract whose Tumors Harbor a TSC1 and / or a TSC2 Mutation
The Phase 1 open - label, multicenter, dose escalation study of mRNA - 2416 is designed to determine the safety and tolerability of escalating iTu doses of mRNA - 2416 in patients with relapsed / refractory solid tumor malignancies or lymphoma, and define the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) and schedule for iTu injections of mRNA - 2416.
Methods: In a multicenter, randomized, patient - and rater - blind, controlled, parallel - group, phase II study, 42 AD patients were assigned (1: 1) to PE treatment or control (sham) groups.
Despite the marginal improvements in survival of patients suffering from malignant glioma treated with gene therapy vectors, the clinical trials conducted so far using viral vectors, in particular adenoviral vectors, have proven that the use of adenoviral vectors is a safe therapeutic approach, even in large, multicenter, phase 3 clinical trials.
Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: A phase II multicenter study.
A phase II multicenter, randomized, open - label trial of T - VEC [28] in patients with resectable stage IIIB, IIIC, or IV M1a melanoma testing that hypothesis is in the enrollment phase.
Our 80 - subject, multicenter, international phase II study [16] enrolled patients with measurable stage III / IV melanoma.
Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T - VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB - IV melanoma.
It was a large multicenter clinical study comprising phase I and phase II portions.